I’ve long argued for PrEP being made available on the NHS, but I do understand that the decision has to be based not just on clinical grounds, but that it also has to meet the NHS applies to all new treatments.
It sounds harsh to look at new treatment, but the NHS is always under pressure – despite ever increasing treatments. I’ve just secured vaccination programme to MSM, I’m campaigning to extend this to all boys, others are campaigning on making new breast cancer drugs available, and meningitis vaccination to be given to all babies. Hence approval takes time.
It’s also worth remembering that the UK continues to prevention and treatment; and we are world leaders in in the developing world. So is not a cure and it is not a vaccine, but it is and can be a would still have to reiterate the message about using aren’t the only ones on the drug-resistant gonorrhoea, we can’t allow ourselves to
The issue is also complicated by the licensing At the moment, it is licensed as a treatment. It is not a preventive measure. That has to be resolved. This is patent issue. Truvada comes would bring down the annual the NHS could have more available, or simply allow the other areas. There is a risk that by making Truvada a preventative and treatment drug, Gilead could seek an keeping the drug at the annum, rather than seeing it drop. The NHS procurement team has to resolve this.
Is the UK out on a limb when the health service is mainly private or insurance based, system are wrestling with the same issues as our NHS.
rapid evidence review that will look at the resource as well as all the clinical world. It will report by This is alongside the trial, which will be larger than available to those most at risk, when a clinician recommends it.
The NHS can be slow but we have to make sure the correct approval processes opportunity to be missed.